As a matter of fact, patients with concomitant psoriatic arthritis (PsA), should be treated with anti-TNF-alfa or anti-IL-17 drugs, while those with a diagnosis or medical history of inflammatory bowel disease should not receive IL-17 inhibitors. This evidence concerns the gene IL17A and inflammatory bowel disease.